2 days Ago By ABMN Staff
Vertex Pharmaceuticals ( NASDAQ:VRTX – Get Free Report ) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday. VRTX has been the subject of several other research reports.
Guggenheim raised their target price on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd.
JPMorgan Chase & Co. cut their price objective on shares of Vertex Pharmaceuticals from $510.00 to $503.
00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $600.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, October 21st.
Oppenheimer lowered their target price on shares of Vertex Pharmaceuticals from $550.00 to $540.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th.
Finally, Cantor Fitzgerald restated an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 5th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock.
According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $504.38.
Get Our Latest Stock Analysis on VRTX Vertex Pharmaceuticals Stock Performance Vertex Pharmaceuticals ( NASDAQ:VRTX – Get Free Report ) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.
61 by $0.77. The firm had revenue of $2.
77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.
91% and a negative net margin of 4.52%. The business’s quarterly revenue was up 11.
6% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.67 earnings per share.
On average, sell-side analysts anticipate that Vertex Pharmaceuticals will post -1.82 earnings per share for the current year. Insider Activity In other Vertex Pharmaceuticals news, Chairman Jeffrey M.
Leiden sold 3,784 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $499.00, for a total value of $1,888,216.
00. Following the transaction, the chairman now directly owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. This trade represents a 27.
46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink . Also, Director Sangeeta N.
Bhatia sold 646 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.
00. Following the completion of the transaction, the director now owns 4,435 shares in the company, valued at $2,217,500. This trade represents a 12.
71 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold a total of 4,445 shares of company stock valued at $2,218,394 in the last 90 days.
0.20% of the stock is currently owned by insiders. Institutional Trading of Vertex Pharmaceuticals Institutional investors and hedge funds have recently added to or reduced their stakes in the business.
Quent Capital LLC boosted its stake in Vertex Pharmaceuticals by 33.0% during the first quarter. Quent Capital LLC now owns 399 shares of the pharmaceutical company’s stock valued at $167,000 after buying an additional 99 shares during the last quarter.
EP Wealth Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 4.4% in the 1st quarter. EP Wealth Advisors LLC now owns 4,709 shares of the pharmaceutical company’s stock worth $1,969,000 after buying an additional 197 shares in the last quarter.
Axxcess Wealth Management LLC raised its position in shares of Vertex Pharmaceuticals by 33.6% during the 1st quarter. Axxcess Wealth Management LLC now owns 2,228 shares of the pharmaceutical company’s stock valued at $931,000 after buying an additional 560 shares in the last quarter.
Sheaff Brock Investment Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 29.7% in the 1st quarter. Sheaff Brock Investment Advisors LLC now owns 1,193 shares of the pharmaceutical company’s stock valued at $499,000 after acquiring an additional 273 shares during the last quarter.
Finally, Canada Pension Plan Investment Board raised its position in Vertex Pharmaceuticals by 8.0% during the first quarter. Canada Pension Plan Investment Board now owns 386,648 shares of the pharmaceutical company’s stock valued at $161,623,000 after purchasing an additional 28,747 shares during the period.
Institutional investors own 90.96% of the company’s stock. About Vertex Pharmaceuticals ( Get Free Report ) Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. Read More Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
